每经AI快讯，10月8日，长风药业港股IPO上市首日开盘大涨超218%，报47港元/股。 ...

Core Viewpoint - Changfeng Pharmaceutical (02652) has successfully listed its shares at a price of HKD 14.75 per share, raising approximately HKD 525 million, with a significant initial trading surge of 218.64% to HKD 47 per share, indicating strong market interest and investor confidence in the company’s prospects [1] Company Overview - Changfeng Pharmaceutical focuses on the research, development, production, and commercialization of inhalation technology and inhalation drugs, specifically targeting respiratory diseases [1] - The company has developed a diverse product portfolio that addresses a wide range of patients, medical specialties, and treatment areas [1] Regulatory Approvals and Market Performance - The company has received six product approvals from the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA), demonstrating its capabilities in clinical development, production, regulatory affairs, and commercialization [1] - CF017, an inhalation suspension of budesonide for the treatment of bronchial asthma, is the company’s first approved product, which quickly became part of China's centralized procurement plan after its approval in May 2021, leading to significant market growth [1] - According to Frost & Sullivan, CF017 is projected to capture approximately 16% of the Chinese budesonide inhalation drug market by sales volume in 2024 [1]

Core Viewpoint - Changfeng Pharmaceutical (02652) has successfully listed its shares at a price of HKD 14.75 per share, raising approximately HKD 525 million, with a significant initial trading increase of 218.64% to HKD 47 per share [1] Company Overview - Changfeng Pharmaceutical focuses on the research, development, production, and commercialization of inhalation technology and inhalation drugs, primarily targeting respiratory diseases [1] - The company has developed a diverse product portfolio that addresses a wide range of patients, medical specialties, and treatment areas [1] Regulatory Approvals and Market Performance - The company has received six product approvals from the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA), demonstrating its capabilities in clinical development, production, regulatory affairs, and commercialization [1] - CF017, an inhalation suspension of budesonide for the treatment of bronchial asthma, is the company's first approved product and has quickly gained market traction since its approval in May 2021 [1] Market Position - CF017 has been included in China's centralized procurement plan, leading to significant market growth [1] - According to Frost & Sullivan, CF017 is projected to capture approximately 16% of the Chinese budesonide inhalation drug market by 2024, based on sales volume [1]

点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 来源：新浪港股-好仓工作室 发行情况： ① 发行价：最终发行价格为14.75港元，公告未提及价格区间。 ② 发行股数：基础发行股 数为41,198,000股H股，未提及超额配售权股数。 ③ 募集资金规模：所得款项总额为6.077亿港元，所得 款项净额为5.254亿港元。 ④ 认购倍数：香港发售认购倍数为6,697.80倍，国际配售认购倍数为12.74 倍。 ⑤ 回拨情况：未触发回拨机制，香港发售股份数目为4,120,000股H股，占全球发售股份数目之 10.00%；国际配售股份数目为37,078,000股H股，占全球发售股份数目之90.00%。 ⑥ 基石投资者：公告 未提及基石 ...

其中，香港公开发售获6697.80倍认购，国际发售获12.74倍认购。 长风药业(02652)发布公告，公司全球发售约4119.8万股股份，香港公开发售占10%，国际发售占90%。 最终发售价为每股14.75港元，全球发售净筹约5.25亿港元。每手500股，预期将于2025年10月8日(星期 三)上午九时正(香港时间)开始在联交所买卖。 ...

其中，香港公开发售获6697.80倍认购，国际发售获12.74倍认购。 智通财经APP讯，长风药业(02652)发布公告，公司全球发售约4119.8万股股份，香港公开发售占10%， 国际发售占90%。最终发售价为每股14.75港元，全球发售净筹约5.25亿港元。每手500股，预期将于 2025年10月8日(星期三)上午九时正(香港时间)开始在联交所买卖。 ...

香港公開發售 長風藥業股份有限公司 最終發售價及配發結果公告 除非本公告另有界定，否則本公告所用詞彙與長風藥業股份有限公司（「本公司」）所刊發日期為 2025 年 9 月 26 日的招股章程（「招股章程」）所界定者具有相同涵義。 | 摘要 | | | --- | --- | | 公司資料 | | | 股份代號 | 2652 | | 股份簡稱 | 長風藥業 | | 開始買賣日 | 2025 年 10 月 8 日* | | * 請參閱本公告底部附註 | | | 價格資料 | | | 最終發售價 | 14.75 港元 | | 發售股份及股本 | | | 發售股份數目 | 41,198,000 H 股 股 | | 香港公開發售項下的最終發售股份數目 | 4,120,000 股 H 股 | | 國際發售項下的最終發售股份數目 | 37,078,000 股 H 股 | | 於上市時已發行的股份數目 | 411,978,387 股股份 | | 所得款項 | | | 所得款項總額（附註） | 607.7 百萬港元 | | 減：基於發售價之預計應付上市開支 | (82.3)百萬港元 | | 所得款項淨額 | 525.4 百萬港 ...

Core Insights - Chronic respiratory diseases (CRDs) have become the fourth leading cause of death globally, highlighting the increasing severity of respiratory issues among modern populations [3] - Changfeng Pharmaceutical, set to list on the Hong Kong Stock Exchange, has successfully transitioned from losses to profitability by focusing on inhalation formulations for respiratory diseases [3][4] - The company employs a two-step strategy: leveraging its established inhalation drug business while pursuing innovative global projects to ensure future growth [4][5] Group 1: Business Model and Financial Performance - Changfeng Pharmaceutical's first strategic step focuses on the Chinese market, targeting globally popular inhalation formulations to achieve domestic substitution through technological breakthroughs [4] - The company's total revenue is projected to increase from RMB 349 million in 2022 to RMB 608 million in 2024, representing a compound annual growth rate (CAGR) of 31.9% [5] - The core product CF017 has captured approximately 16% of the Chinese budesonide inhalation drug market by 2024, driving significant revenue growth [5][6] Group 2: Technological and Competitive Advantages - Changfeng Pharmaceutical has established five key technology platforms that span the entire inhalation drug development process, providing a competitive edge in the complex inhalation formulation market [5][6] - The company is the only developer currently conducting clinical trials for CF006/CF043, which targets a market with sales of RMB 1.8 billion, ensuring a unique position in the competitive landscape [6][8] Group 3: Innovation Pipeline and Future Growth - The company is advancing into innovative drug development for severe diseases such as idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH), which have poor prognoses and limited treatment options [8][9] - Changfeng Pharmaceutical is also exploring the CNS market with innovative delivery methods, such as nasal sprays for migraine and cluster seizures, aiming to enhance patient experience and treatment efficacy [9][10] - The company is developing groundbreaking inhaled siRNA therapies, which could revolutionize the treatment of chronic respiratory diseases by targeting disease pathways at the genetic level [10][11] Group 4: Investment Proposition - Changfeng Pharmaceutical presents a dual value proposition: a stable revenue stream from its established inhalation drug business and significant growth potential from its innovative pipeline [11] - The upcoming IPO funds will support both the commercialization of existing products and the clinical research of innovative projects, reinforcing the company's business model and growth trajectory [11]

Core Insights - Changfeng Pharmaceutical (2652.HK), focused on treating respiratory diseases, saw its stock price surge significantly after its listing, with a dark market price increase of 2.2 times [1] Company Performance - The stock reached a peak price of 62 HKD, which is 3.2 times higher than the IPO price of 14.75 HKD, before closing at 48.3 HKD, reflecting a gain of 33.55 HKD or 227.46% [1][2] - The trading volume was 2.9885 million shares, with a total transaction value of 1.49 billion HKD [2] - The average price during trading was 50.005 HKD, with a price fluctuation of 225.09% [2] Financial Metrics - The company has a total market capitalization of 19.899 billion HKD and a total share count of 412 million [2] - The stock's price-to-earnings ratio (P/E) is reported at 661.64 (ITM) and 862.50 (static) [2] - The stock's price-to-book ratio (P/B) stands at 19.038 [2]

智通财经APP获悉，长风药业(02652)将于10月8日(周三)在香港挂牌。截至收盘，利弗莫尔证券暗盘交易显示报价46.9港元，较招股价14.75港元上涨 217.97%，每手500股，不计手续费，每手赚16075港元。 分时量 量:0 98000 46.860 46.840 46.820 46.800 MACD(12,26,9) :- 0.081 DIF:0.006 DEA:0.046 MACD 46.780 46.760 46.740 46.720 16:15 18:30 分时 1分 5分 日K · 行情来源: 利弗莫尔证券 · ...